We can't find the internet
Attempting to reconnect
35811.1 IP-LS
35811.1 IP-LS
Résumé
Preclinical development of innovative drug candidates for the treatment of glaucoma.
Textes supplémentaires
Abstract
Glaucoma is the second leading cause of blindness worldwide after cataracts. New treatments are needed to address a high unmet medical need. Our approach is to target neuroprotection by addressing two established risk factors as ocular blood flow and intraocular pressure.
Participants
Paola Atzei
Wirtschaftspartner
paola.atzei@topadur.com
Topadur Pharma AG CHE-481.951.668 Paola Atzei Grabenstrasse 11a 8952 Schlieren ZH CH
Christian Grimm
Kontaktperson
cgrimm@opht.uzh.ch
Universität Zürich Christian Grimm Wagistrasse 14 8952 Schlieren ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2019-09-30
- Date de fin
- 2021-12-31
- Coûts totaux approuvés
- CHF 759834.50
- Section
- 60 Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T410 Pharmaceuticals and related technologies 100.0%